Markets

Insider Trading

Hedge Funds

Retirement

Opinion

1281292 - 11759070 - 1

9 Most Undervalued Healthcare Stocks to Buy Now

Page 1 of 3

In this article, we will be taking a look at the 9 Most Undervalued Healthcare Stocks to Buy Now.

On April 17, Matt Powers, managing partner at Powers Advisory Group, appeared on CNBC’s Squawk Box to discuss the forces shaping current market behavior. The latest market response to global concerns, according to him, was a “textbook” V-shaped move, with a fast sell-off and a quick comeback. Notably, despite a war headline and a sharp increase in oil prices, the S&P 500 reached its highs in around 15 trading days. The market showed underlying strength and tenacity as it hardly approached the correction area. Powers claimed that until additional geopolitical escalations occur, a large portion of the macro risk had already been priced in, indicating a near-term bottom. However, he stressed that markets are still very susceptible to news, especially when it comes to oil, geopolitics, and the timing of the Federal Reserve.

The first quarter has been characterized by this volatility, as the S&P 500 has fluctuated between all-time highs and a decline. Investors are uneasy due to worries about high valuations, economic instability brought on by tensions in the Middle East, and inflation brought on by growing energy prices. Capital has started to shift away from large-cap technology equities in reaction. John Stoltzfus of Oppenheimer, meanwhile, sees this as a more comprehensive diversification strategy in which investors reallocate gains across industries rather than a retreat from technology.

Traditionally a defensive strategy, healthcare has found it difficult to profit from this change. Due to pressure from post-COVID earnings normalization and policy-related valuation concerns, the sector is down around 4% so far this year, trailing a flat broader index. JPMorgan analysts saw evidence of stabilization despite slower earnings growth over the previous five years, indicating that the worst may be behind us.

At the same time, industry fundamentals are being strengthened by increased merger and acquisition activity. This has raised awareness of inexpensive healthcare stocks, especially those backed by insider purchases, which are frequently seen as a powerful signal in an industry that is influenced by changes in clinical, regulatory, and mood. Institutional investors echo this optimism, supported by Deloitte’s February 16, 2026, Global Health Care Outlook, which highlights a sector navigating short-term challenges but positioned for long-term growth, with over 70% of non-US executives expecting higher revenues and profits.

With that said, let’s take a look at the most undervalued stocks.

Our Methodology

For our methodology, we screened for stocks with a P/E below 15 and positive upside. From the filtered list, we picked stocks with the most recent developments and news and ranked them according to their PE ratios.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

Here is our list of the 9 most undervalued healthcare stocks to buy now.

9. Elevance Health, Inc. (NYSE:ELV)

PE Ratio: 13.02

Elevance Health, Inc. (NYSE:ELV) is one of the most undervalued stocks on this list.

TheFly reported on April 20 that Jefferies analyst David Windley revised his outlook on ELV, trimming the firm’s price target to $391 from $395 while maintaining a Buy rating on the stock. The adjustment follows a detailed evaluation of health insurance offerings within the Health Insurance Exchange market. Based on this deeper analysis, the firm updated its financial projections across its managed care coverage, reflecting refined assumptions tied to plan dynamics and market conditions in the exchange segment.

Separately, earlier on March 31, Elevance Health, Inc. (NYSE:ELV) announced a set of senior leadership changes spanning its Health Benefits segment and Carelon services division to support operational execution and long-term growth. The restructuring is intended to improve coordination across business units, enhance efficiency, and accelerate decision-making as the company expands its services platform.

Carelon, which delivers healthcare, pharmacy, behavioral, and data-driven solutions to a large consumer base, remains a key focus of this strategy. The updated leadership structure also aims to strengthen integration with the Health Benefits business, enabling more aligned offerings that improve care outcomes, reduce costs, and simplify the overall healthcare experience for members while supporting sustained enterprise performance.

Elevance Health, Inc. (NYSE:ELV) is a U.S. health company providing managed care and health solutions to over 119 million people. It operates across commercial, Medicare, and Medicaid markets through brands like Anthem Blue Cross Blue Shield, WellPoint, and Carelon.

8. The Cigna Group (NYSE:CI)

PE Ratio: 12.48

The Cigna Group (NYSE:CI) is one of the most undervalued stocks to invest in.

TheFly reported on April 20 that Jefferies reaffirmed its Buy recommendation on CI while slightly reducing its price objective from $333 to $330 after revising its outlook for managed care companies based on a detailed review of Health Insurance Exchange plan offerings.

Additionally, on April 16, The Cigna Group (NYSE:CI) Foundation announced the expansion of its Impact Fund into Memphis, aiming to support local nonprofits working to improve community health outcomes. Eligible organizations can apply for funding of up to $250,000 distributed over two years to advance initiatives focused on increasing access to primary healthcare services and promoting nutrition, healthy food availability, and lifestyle improvements. Applications must be submitted by May 15, 2026, with selected groups entering grant terms beginning December 1, 2026, through December 1, 2028.

In addition to financial support, participating nonprofits will collaborate with health experts and Foundation representatives through annual meetings to share progress and strategies. The initiative builds on prior investments targeting social drivers of health and reflects a continued commitment to addressing healthcare access challenges, including provider shortages, transportation barriers, and limited availability of affordable, nutritious food in underserved Memphis communities.

The Cigna Group (NYSE:CI) is a global health services and insurance company based in Connecticut, serving over 180 million customer relationships. It operates through Cigna Healthcare and Evernorth Health Services, offering health benefits, pharmacy, and care solutions.

Page 1 of 3

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

 

Wall Street calls this $3 stock a “Melting Ice Cube.” They said the same thing about BTI before it returned 90%.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.